MEDICURE INC
Form 6-K November 22, 2017
1.0 veinoei 22, 2017
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Washington, D.C. 2004)
FORM 6-K
PERCORN OF FOREVOLVENIA THE VOCAMED DATE OF THE ALL OF A LACOR AT LAC
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
UNDER THE SECURITIES EXCHANGE ACT OF 1934
UNDER THE SECURITIES EXCHANGE ACT OF 1934  For the month of November 2017
For the month of <b>November 2017</b>
For the month of <b>November 2017</b> Commission File Number: <b>001-31995</b>
For the month of <b>November 2017</b>
For the month of <b>November 2017</b> Commission File Number: <b>001-31995</b>
For the month of <b>November 2017</b> Commission File Number: <b>001-31995</b> MEDICURE INC.

### 2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule $101(b)(1)$ : o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72

#### **EXHIBIT LIST**

### Exhibit Title

- 99.1 Financial Statements
- 99.2 **MD&A**
- 99.3 **CEO Certification**
- 99.4 **CFO Certification**

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Medicure Inc.** (Registrant)

Date: November 21, 2017 By:/s/ Albert D. Friesen
Albert D. Friesen
Chief Executive Officer